Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595.

Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. Abstract Text:

    o d hughesO D Hughes,a c perkinsA C Perkins,m frierM Frier,m l wastieM L Wastie,g dentonG Denton,m r priceM R Price,h denleyH Denley,m c bishopM C Bishop,

    OBJECTIVE: To investigate the clinical application of an 111In-labelled anti-MUC1 mucin monoclonal antibody (mAb) imaging for staging invasive bladder cancer. PATIENTS AND METHODS: Indirect immunohistochemistry was used to confirm the expression of the MUC1 target antigen by metastatic tumours. Twelve patients with bladder cancer (two with superficial and 10 with locally invasive/metastatic disease) underwent planar gamma-scintigraphy 48 h after an intravenous injection with 111In-labelled anti-MUC1 mucin mAb C595. RESULTS: No bladder uptake was detected in the two patients with superficial disease, but scintigraphy showed primary and recurrent bladder tumours and metastases in nine of the remaining 10 patients with invasive disease. In three patients additional staging information was obtained from the mAb imaging which would have altered patient management. There were no reported side-effects. CONCLUSION: This study confirmed the ability of the mAb technique to detect both primary and recurrent invasive bladder tumours and distant metastases. Some lesions shown by mAb imaging were not detected by other methods. The use of mAb imaging has the potential to improve clinical staging and assist in selecting those patients most likely to benefit from radical therapy.

    Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. Publishing Authors By Initials

    od hughesOD Hughes,ac perkinsAC Perkins,m frierM Frier,ml wastieML Wastie,g dentonG Denton,mr priceMR Price,h denleyH Denley,mc bishopMC Bishop,

    For similar neoplasms: neoplasms by site: urogenital neoplasms: urologic neoplasms: urinary bladder neoplasms research abstracts see: neoplasms: neoplasms by site: urogenital neoplasms: urologic neoplasms: urinary bladder neoplasms research

    PUBMED ID PMID:

    MEDLINE DATE:

    Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: BJU international

    VOLUME: 87

    Page Numbers: 39-46

    Journal Abbreviation: BJU Int.

    ISSN: 1464-4096

    DAY: 1

    MONTH: Jan

    YEAR: 2001

    Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 100886721

    Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. Keywords Mesh Terms:

    KEYWORDS: Urinary Bladder Neoplasms

    MESH TERMS: radionuclide imaging

    Chemical & Substance for Abstract: Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. Information

    Substance Name: Peptide Fragments

    Registry Number: 0

    Grant and Affiliation Information for Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595.

    AFFILIATION: Department of Urology, City Hospital, Nottingham, UK.

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: BJU Int

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595 Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News